Upstroke Time Measured by Photoplethysmography

Last updated: January 29, 2024
Sponsor: Centre Hospitalier Universitaire de Nice
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetic Neuropathy

Diabetic Retinopathy

Diabetic Macular Edema

Treatment

POPMETRE® (Axelife , France)

Clinical Study ID

NCT05795582
22-AOI-07
  • Ages > 18
  • All Genders

Study Summary

Peripherial arterial disease (PAD) and diabetes are major public health issues. In 2020, according to the latest epidemiological data, it is estimated that there will be more than one million patients with PAD and more than 3.5 million diabetic patients in France.

In the diabetic patient, screening for PAD is carried out by calculating the Toe-Brachial pressure index (TBi), a technique that remains time-consuming and technically demanding, which limits its use for clinical routine screening.

A new photoplethysmographic method (PPG) makes possible to determine the quality of peripheral perfusion thanks to the automatic computation of the upstroke time (TMS in ms).

This method appears to be a promising, inexpensive, faster and easier technical alternative to improve the dissemination of the vascular screening in diabetics.

To date, no prospective study has established a relationship between the measurement of upstroke time using the PPG method and TBi in a specific diabetic population.We will perform a two-centre prospective study (Nice University Hospital and Antibes Hospital) comparing the two techniques. The main objective of our study will compare the values of the upstroke time obtained by a PPG method and the TBi in a population of diabetic patients.

The secondary objectives will be to compare the TBi values to the ratio of the TMS measurements at the toe to the reference TMS measured at the hand and to determine the sensitivity-specificity of the TMS measured by PPG compared to the TBi in the detection of a significant PAD in diabetics.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient > 18 years, with no upper age limit
  • Vascular assessment for PAD (screening or follow-up).
  • Patient diagnosed with type 2 diabetes according to WHO diagnostic criteria (bloodglucose > 1.26 g/l (7.0 mmol/l) after an 8-hour fast and checked twice ; or thepresence of symptoms of diabetes (polyuria, polydipsia, weight loss) associated with ablood glucose level (on venous plasma) > 2 g/l (11.1 mmol/l); or a blood glucose level (on venous plasma) > 2 g/l (11.1 mmol/l) 2 hours after an oral glucose load of 75 g),under medical treatment or under dietary treatment alone.
  • Patient having signed the informed consent form for the study.
  • Patient with social security coverage.

Exclusion

Exclusion Criteria:

  • Patient under 18 years of age
  • Major amputations including transfemoral and transtibial amputations
  • Ankle or toe lesions
  • Any clinical condition of the patient not allowing measurements (acute ischaemia,pain, tremors...).
  • Pregnant women, pregnant and breast feeding women, persons deprived of their freedomby a judicial or administrative decision, persons hospitalised without consent who arenot covered by the provisions of Article L. 1121-8, and persons admitted to a healthor social establishment for purposes other than research.

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: POPMETRE® (Axelife , France)
Phase:
Study Start date:
June 14, 2023
Estimated Completion Date:
November 14, 2025

Connect with a study center

  • CH d'Antibes

    Antibes,
    France

    Active - Recruiting

  • CHU de Nice

    Nice, 06000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.